ClinicalTrials.gg
Not yet recruitingNCT07860775HOVON 180 CLLUpdated Oct 6, 2026

Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

A Phase 2 interventional study of pirtobrutinib combined with epcoritamab in CLL / SLL, sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland. Not yet recruiting at 17 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland · Phase 2, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The Haemato Oncology Foundation for Adults in the Netherlands (HOVON) has designed this study. Researchers (all doctors) are conducting the study at various hospitals in the Netherlands, Denmark and Sweden.

The study medicines pirtobrutinib and epcoritamab that are used in this study are made available by pharmaceutical companies Eli Lilly and AbbVie. This study is also funded by AbbVie and Eli Lilly.

HOVON needs 70 participants for this study.

The purpose of this study is to find out how safe and effective the combination of pirtobrutinib tablets and subcutaneous epcoritamab is for patients with CLL whose disease has come back after previous treatment or whose disease did not respond well to the previous treatment. The goal is to suppress the CLL to such an extent that the disease does not come back for a long time.

Read the detailed description

CLL is a chronic disease. Although the treatment is improving all the time, there is still no cure. If the disease comes back patients will receive another treatment, but with each subsequent treatment the disease usually comes back sooner.

This study investigates a treatment consisting of pirtobrutinib in combination with epcoritamab. Pirtobrutinib has been approved in Europe for the treatment of CLL if the disease comes back after previous treatment. Pirtobrutinib blocks important cancer cell signals. These signals help the cells to divide and survive. It is known that pirtobrutinib is effective in patients who did not respond well to other medicines that work in a similar way (ibrutinib, acalabrutinib and zanubrutinib).

Epcoritamab is what is called a bispecific antibody. This means that it is able to bind to cells that are part of our immune system (T cells) and to tumor cells (CLL cells). This enables epcoritamab to help these T cells recognize and attack the tumor cells. The first studies of epcoritamab in patients with other types of lymphatic cancer have shown that it can be an effective treatment. Epcoritamab has been approved in Europe for certain types of lymphatic cancer where the disease has come back. Epcoritamab has also been studied in CLL patients whose disease has come back and in most cases resulted in decreased CLL with acceptable side effects.

02

Conditions studied

  • CLL / SLL

Keywords

  • HOVON 180 CLL
03

In context

Lead sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland is the lead sponsor of 27 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

In order to be eligible to participate in this study, a patient must meet all of the following criteria:

  • Documented CLL or SLL (SLL in Cohort Expansion only) following at least one systemic treatment
  • Requiring treatment according to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria;
  • Age at least 18 years;
  • (ECOG)/World Health Organization (WHO) performance status 0-2;
  • Adequate BM function defined as:

    • (Hb) >5 mmol/l or >8 g/dL.
    • (ANC) >1.0 x 109/L (1,000/μL)
    • count >30 x 109/L (30,000/μL); Please note: If the patient is cytopenic there should be no evidence of myelodysplasia or hypoplastic bone marrow.
  • Estimated (eGFR) Modification of Diet in Renal Disease (MDRD) or estimated (CrCl) ≥ 45 ml/min (Cockcroft-Gault);
  • Adequate liver function as indicated:

    • Serum (AS(A)T) and alanine transaminase (AL(A)T) ≤ 3.0 x (ULN);
    • ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or controlled hemolytic anemia);
  • (PT)/International normal ratio (INR) \<1.5x ULN and activated partial thromboplastin time (aPTT) \<1.5 x ULN;
  • Patients must have negative serological testing for and C, defined as negative hepatitis B surface antigen (HBsAg) and negative hepatitis B core antibody (anti-HBc), as well as negative antibody.

    • Participants who are hepatitis B core antibody (anti-HBc) positive and HBsAg negative, or who are hepatitis C antibody positive, may be eligible if hepatitis B deoxyribonucleic acid (HBV-DNA) or hepatitis C ribonucleic acid (HCV-RNA) polymerase chain reaction (PCR), respectively, is negative within 6 weeks prior to enrolment. Participants with a positive HBV-DNA or HCV-RNA PCR will be excluded.

Please note:

Patients who are anti-HBc positive, HBsAg negative, and HBV-DNA negative and will be treated with pirtobrutinib in combination with a B-cell-depleting agent (e.g., rituximab, obinutuzumab or epcoritamab) must receive prophylactic antiviral therapy with a nucleos(t)ide analogue (e.g., entecavir or tenofovir), starting prior to treatment initiation and continuing for 6-12 months after completion of study treatment.

  • For patients who are anti-HBc positive or hepatitis C antibody positive, HBV-DNA or HCV-RNA PCR, respectively, must be monitored every 1 to 3 months during study treatment and for at least 6 months after the last dose.
  • If HBV-DNA becomes detectable during study treatment, it is recommended to initiate antiviral therapy (e.g., entecavir or tenofovir) and to discontinue pirtobrutinib.

    • Patient is able and willing to adhere to the study visit schedule and other protocol requirements;
    • Patient is capable of giving ;
    • Written informed consent.

A patient who meets any of the following criteria cannot be included in this study:

♦ The patient has received any of the following anticancer therapies:

o Targeted therapies, agents, therapeutic monoclonal antibodies, or cytotoxic chemotherapy within either: 5 drug half-lives, or 2 weeks prior to the first dose of study treatment, whichever is shorter.

Exception: Anti-CD20 monoclonal antibodies, covalent BTK inhibitors, and BCL2 inhibitors are permitted and may be continued up to the first dose of pirtobrutinib.

  • Immunoconjugated antibody treatment within 10 weeks or 5 half-lives, whichever is shorter
  • Broad field radiation (≥ 30% of the bone marrow or whole brain radiotherapy) within 14 days
  • Palliative limited field radiation within 7 days
  • Prior treatment with a CD3 × CD20 bispecific antibody
  • Prior treatment with pirtobrutinib within 24 months
  • CAR-T-cell therapy within 100 days prior to first dose of study drug or need of anti-cytokine therapy for toxicity from CAR-T therapy and/or residual symptoms of neurotoxicity > Grade 1 from CAR-T therapy

    • Transformation of CLL (Richter's transformation);
    • Known central nervous system involvement
    • Prior stem cell transplantation and/or solid organ transplantation;
    • Patient with a history of confirmed progressive multifocal leukoencephalopathy (PML);
    • Current autoimmune disease-requiring therapy except for up to 20 mg daily prednisone or equivalent.
    • Current seizure disorder requiring therapy
    • Active tuberculose (TB) or history of completed treatment for active TB within the past 12 months.
    • Patient receiving anti-coagulation therapy (e.g. warfarin, vitamin K antagonists, phenprocoumon).

Please note: Patients being treated with direct oral anticoagulants (DOACs) can be included, but must be properly informed about the potential risk of bleeding under treatment;

  • other than CLL/SLL unless in remission defined as treated non-melanoma skin cancer or other neoplasias treated curatively ≥ 1 year ago, without signs of progression and not requiring systemic therapies (with the exception of ongoing anti-hormonal therapy);
  • Known allergy to xanthine oxidase inhibitors and/or rasburicase;
  • History of severe allergic or anaphylactic reactions to anti-CD20 monoclonal or bi-specific antibody therapy, or known significant allergy or intolerance to any component or constituents of the study treatment (and their excipients) and/or other products in the same class;
  • History of bleeding diathesis;
  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) within 2 weeks prior to first dose of study treatment;
  • Known active cytomegalovirus (CMV) infection;
  • Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled: infection, auto- immune hemolysis, immune thrombocytopenia, diabetes, hypertension, hyperthyroidism or hypothyroidism etc.);
  • Patient known to be (HIV)-positive;
  • grade III-IV cardiovascular disease including but not limited to:

Significant cardiovascular disease defined as:

  • unstable angina or acute coronary syndrome within the past 3 months prior to treatment initiation or a history of myocardial infarction within 3 months prior to treatment initiation or
  • documented (LVEF) by any method of ≤ 40% in the 12 months prior to treatment initiation
  • ≥ Grade 3 (NYHA) functional classification system of heart failure
  • Uncontrolled or symptomatic arrhythmias ♦ Screening 12-lead (ECG) showing a baseline (Q and T wave) interval as corrected by Fridericia's formula (QTcF) >480 msec.

Please note: this criterion does not apply to patients with a left bundle branch block.

  • Stroke or intracranial hemorrhage within 6 months prior to registration.
  • Severe pulmonary dysfunction (CTCAE grade III-IV);
  • Severe neurological or psychiatric disease (CTCAE grade III-IV);
  • Neuropathy > CTCAE grade II;
  • Patient who has difficulty with or is unable to swallow oral medication, or has significant gastrointestinal disease that would limit absorption of oral medication;
  • Vaccination with within 28 days prior to registration;
  • Use of any other experimental drug or therapy within 28 days of registration;
  • Major surgery within 28 days prior to registration;
  • Pregnant women and nursing mothers;
  • Fertile men or women of (WOCBP) unless: (1) surgically sterile or ≥ 2 years after the onset of menopause; (2) willing to use a highly effective method such as oral contraceptives, intrauterine device, sexual abstinence or combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) during study treatment and for 4 months after last dose of epcoritamab and 5 weeks (women) or 3 months (men) after last dose of pirtobrutinib;
  • Patients who are planning egg donation (ova, oocytes) for the purposes of assisted reproduction or sperm donation during study treatment, until 4 months after last dose of epcoritamab and 5 weeks after last dose of pirtobrutinib for egg donation and 3 months after last dose of pirtobrutinib for sperm donation;
  • Current participation in other clinical trial and using study medication;
  • Any psychological, familial, sociological and geographical condition potentially hampering ompliance with the study protocol and follow-up schedule
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Pirtobrutinib combined with epcoritamab

    Pirtobrutinib combined with epcoritamab

    Combination Product: pirtobrutinib combined with epcoritamab

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate efficacy in terms of Progression-free survival (PFS)

    To evaluate efficacy in terms of Progression-free survival (PFS) at 24 months after first dose of pirtobrutinib.

    Time frame: 24 months after first dose of pirtobrutinib.

07

Study locations

17 sites
  • DK-Copenhagen-Rigshospitalet
    Copenhagen, Denmark
  • NL-Almere-Flevoziekenhuis
    Almere Stad, Netherlands
  • NL-Amersfoort-Meander MC
    Amersfoort, Netherlands
  • NL-Amsterdam-AUMC
    Amsterdam, Netherlands
  • NL-Amsterdam-OLVG
    Amsterdam, Netherlands
  • NL-Breda-Amphia ziekenhuis
    Breda, Netherlands
  • NL-Doetinchem-Slingeland
    Doetinchem, Netherlands
  • NL-Dordrecht-ASZ
    Dordrecht, Netherlands
  • NL-eindhoven-Maxima MC
    Eindhoven, Netherlands
  • NL-Groningen-Martini Ziekenhuis
    Groningen, Netherlands
  • NL-Hoofdorp-Spaarne Gasthuis
    Hoofddorp, Netherlands
  • NL-Leeuwarden-Frisius MC
    Leeuwarden, Netherlands
  • NL-Nieuwegein-Antonius Ziekenhuis
    Nieuwegein, Netherlands
  • NL-Rotterdam-Ikazia ziekenhuis
    Rotterdam, Netherlands
  • NL-Rotterdam-Maasstad Ziekenhuis
    Rotterdam, Netherlands
  • NL-Den Haag-HMC
    The Hague, Netherlands
  • SE-Orebro-Orebro UH
    Örebro, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Oct 2030, 49 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Oct 6, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Oct 15, 2030
CompletionEst.
Oct 15, 2032
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860775
Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Oct 15, 2030 (estimated)
Completion
Oct 15, 2032 (estimated)
Last update
Oct 6, 2026

Study contacts

Arnon Kater, Prof. dr
Contact
a.p.kater@amsterdamumc.nl
+31 20 44 42604
Sabina Kersting, dr.
Contact
s.kersting@hagaziekenhuis.nl

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pirtobrutinib · Epcoritamab

Start the discussion